tbuckley/cabot-search huggingface dataset:
SDX-308, a Structural Analog of Etodolac, Inhibits NF-κB Activity Resulting in Significant Inhibition of Osteoclast Formation/Activity and Multiple Myeloma Cell Growth.
Authors: Rentian Feng, Gulsum Anderson, Guozhi Xiao, Gary Elliott, Lorenzo M. Leoni, Markus Y. Mapara, David Roodman, Suzanne Lentzsch
Journal: Blood (2006)
Adjuvant therapy in pancreatic adenocarcinoma: A systemic review and meta-analysis.
Authors: Kazi Jannatun Nahar, David Chan, Anubhav Mittal, Jaswinder S. Samra, Thomas Hugh, Connie Irene Diakos, Stephen John Clarke, Nick Pavlakis
Journal: Journal of Clinical Oncology (2016)

330 Background: The “optimal” adjuvant treatment in pancreatic cancer remains undetermined. Chemotherapy (chemo) such as gemcitabine (Gem), 5-fluorouracil (5-FU) and chemo-radiotherapy (chemoRT) with either Gem or 5-FU have been investigated in trials. We performed a systematic review and meta-analysis to determine the overall efficacy of adjuvant treatment. Methods: We searched databases (PubMed, Medline, Cochrane database) and major conference proceedings up until August 2015 for randomized trials comparing chemo or chemoRT versus (vs) observation, two different chemo regimens and chemoRT vs chemo. Primary end point was overall survival (OS); secondary end points were relapse free survival (RFS), grade 3/4 toxic effects and quality of life (QoL). We performed meta-analysis as per the PRISMA guidelines; hazard ratios (HR) for OS and RFS were pooled with random-effects modelling. Results: Fifteen trials were identified evaluating 4348 patients. For trials comparing chemo to observation (7 trials, n = 1383) the OS HR was 0.77 (95% CI 0.67-0.89, p = 0.001) and PFS HR 0.73 (95% CI 0.53-1.01, p = 0.06) both favouring chemo. For trials investigating Gem (2 trials, n = 472), OS was improved with HR 0.76 (95% CI 0.63 -0.92, p = 0.006) as was RFS (HR 0.56, 95% CI 0.46-0.68, p &lt; 0.00001). For trials investigating agents other than Gem (5 trials, n = 911), OS was improved with HR 0.79 (95% CI 0.63-0.99, p = 0.04), but RFS was not (2 trials only, HR 1.00, 95% CI 0.73-1.37, p = 0.99). Five trials (n = 1832) compared different chemo regimens to Gem in each case; pooled OS HR was 0.90 (95% CI 0.65-1.25, p = 0.54) and RFS HR 0.88 (95% CI 0.67-1.15, p = 0.35). Insufficient data was available to pool grade 3/4 toxicity for chemo vs observation trials; no significant difference was found in incidence of overall grade 3/4 toxicity for trials comparing two chemo regimens (OR 0.98, 95% CI 0.39-2.47, p = 0.96). QoL data was available in 3 trials (ESPAC-1, ESPAC-3, CapRi) with no significant differences noted. Conclusions: Adjuvant chemo vs no chemo for resected pancreatic adenocarcinoma improves OS and RFS. Adjuvant ChemoRT vs no treatment is not beneficial. Overall, novel chemo regimens have not been shown to be superior to Gem. Reporting of QoL is inadequate to make any conclusion.
Abstract B18: CXCL10 suppresses tumor angiogenesis and impedes expression of critical angiogenic factors in renal cell carcinoma
Authors: Hyun A Jin, Jun Hyeok Heo, You Hyun Kang, Ki Hong Kim, Kyung Suk Han, Sung Joon Hong
Journal: Cancer Research (2016)

Abstract Background: Angiogenic progress is complex and several factors are involved as a promoter or inhibitor of angiogenesis. Tumor can use the imbalance of pro- and antiangiogenic factors in progression. The CXC chemokine family are consisted of pro- or antiangiogenic factors. Recent studies revealed CXCL10 as an anti-angiogenic factor in response to angiogenic factors like bFGF or VEGF. However, a role of CXCL10 in cancer and angiogenesis is unclear. Here, we investigated the role of CXCL10 on tumor angiogenesis and its mechanisms in renal cell carcinoma. Methods: Human vascular endothelial cell (HUVEC) was used to evaluate the effects of CXCL10 on endothelial cells. MTS assay was performed to assess cell proliferation. Cell cycle analysis was performed using flow cytometry with propidium iodide. RT-PCR and western blot were performed to assess the baseline expression of CXCL10 in a panel of renal cell carcinoma cells. Overexpression of CXCL10 was developed by lentiviral transfection. Quantitative RT-PCR for angiogenic factors (VEGF, PDGF, FGF, MMP9) was performed by angiogenesis multigene screening array. Subcutaneous tumor xenografts were developed using Caki-1 cells to evaluate in vivo effects of CXCL10. Results: CXCL10 inhibited proliferation and tube formation of HUVEC in a dose-dependent manner, while it did not affect in vitro tumor proliferation of renal cell carcinoma cells. Expression of CXCL10 was downregulated in Caki-1, UMRC3 and UMRC6 cells. Overexpression of CXCL10 suppressed expression of angiogenic factors including VEGF-A, PDGF, FGF2 and MMP9 in Caki-1 cells, suggesting that CXCL10 is involved non only as an anti-angiogenic factor but also as a suppressor of critical angiogenic factors in renal cell carcinoma. In vivo Restoration of CXCL10 expression suppresses tumor growth in renal cell carcinoma by suppressing tumor angiogenesis in xenografts. Conclusions: CXCL10 has a role as an anti-angiogenic factor and also as a suppressor of critical angiogenic factors in renal cell carcinoma. Restoration of CXCL10 expression suppresses tumor growth in renal cell carcinoma by impeding expression of other angiogenic factors including VEGF, PDGF, FGF, MMP9 in renal cell carcinoma as well as inducing anti-angiogenic effect on endothelial cells. Our data suggest that targeting CXCL10 might be a novel therapeutic option for advanced renal cell carcinoma. Citation Format: Hyun A Jin, Jun Hyeok Heo, You Hyun Kang, Ki Hong Kim, Kyung Suk Han, Sung Joon Hong. CXCL10 suppresses tumor angiogenesis and impedes expression of critical angiogenic factors in renal cell carcinoma. [abstract]. In: Proceedings of the AACR Special Conference: Function of Tumor Microenvironment in Cancer Progression; 2016 Jan 7–10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2016;76(15 Suppl):Abstract nr B18.
HB Florida: A New Elongated C-Terminal β-Globin Variant Causing Dominant β-Thalassemia.
Authors: Maria F. Sonati, Beatriz I. Weinstein, Beatriz Erramouspe, Dulcineia M. Albuquerque, Elza M. Kimura, Denise M. Oliveira, Fernando F. Costa
Journal: Blood (2004)
The reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index ( <scp>CDASI</scp> ) among dermatologists, rheumatologists and neurologists
Authors: J. Tiao, R. Feng, S. Bird, J.K. Choi, J. Dunham, M. George, T.C. Gonzalez‐Rivera, J.L. Kaufman, N. Khan, J.J. Luo, R. Micheletti, A.S. Payne, R. Price, C. Quinn, A.I. Rubin, A.G. Sreih, P. Thomas, J. Okawa, V.P. Werth
Journal: British Journal of Dermatology (2016)

Previous studies have shown that skin disease in dermatomyositis (DM) is best assessed using the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI). Although the CDASI has been validated for use by dermatologists, it has not been validated for use by other physicians such as rheumatologists and neurologists, who also manage patients with DM and assess skin activity in clinical trials.To assess the reliability of the CDASI among dermatologists, rheumatologists and neurologists.Fifteen patients with cutaneous DM were assessed using the CDASI and the Physician Global Assessment (PGA) by five dermatologists, five rheumatologists and five neurologists.The mean CDASI activity scores for dermatologists, rheumatologists and neurologists were 21·0, 21·8 and 20·8, respectively. These mean scores were not different among the specialists. The CDASI damage score means for dermatologists, rheumatologists and neurologists were 5·3, 7·0 and 4·8, respectively. The mean scores between dermatologists and rheumatologists were significantly different, but the means between dermatologists and neurologists were not. The intraclass correlation coefficients (ICCs) for interrater reliability for CDASI activity and damage were good to excellent for dermatologists and rheumatologists, and moderate to excellent for neurologists. The ICCs for intrarater reliability for CDASI activity and damage were excellent for dermatologists and rheumatologists and moderate to excellent for neurologists. The PGA displayed lower interrater and intrarater reliability relative to the CDASI.Our results confirm the reliability of the CDASI when used by dermatologists and rheumatologists. The data for its use by neurologists were not as robust.
The history, geography, and sociology of slums and the health problems of people who live in slums
Authors: Alex Ezeh, Oyinlola Oyebode, David Satterthwaite, Yen-Fu Chen, Robert Ndugwa, Jo Sartori, Blessing Mberu, G J Melendez-Torres, Tilahun Haregu, Samuel I Watson, Waleska Caiaffa, Anthony Capon, Richard J Lilford
Journal: The Lancet (2016)
A novel hemostatic powder for upper gastrointestinal bleeding: a multicenter study (the “GRAPHE” registry)
Authors: Sami Haddara, Jeremie Jacques, Stéphane Lecleire, Julien Branche, Sarah Leblanc, Yann Le Baleur, Jocelyn Privat, Laurent Heyries, Philippe Bichard, Philippe Granval, Ulriikka Chaput, Stephane Koch, Jonathan Levy, Bruno Godart, Antoine Charachon, Jean-François Bourgaux, Elodie Metivier-Cesbron, Edouard Chabrun, Vincent Quentin, Bastien Perrot, Geoffroy Vanbiervliet, Emmanuel Coron
Journal: Endoscopy (2016)

<b>Background and study aims:</b> The hemostatic powder TC-325 (Hemospray; Cook Medical, Winston-Salem, North Carolina, USA) has shown promising results in the treatment of upper gastrointestinal bleeding (UGIB) in expert centers in pilot studies. The aim of this study was to evaluate the feasibility and efficacy of TC-325 in a large prospective registry of use in routine practice. <b>Patients and methods:</b> The data of all patients treated with TC-325 were prospectively collected through a national registry. Outcomes were the immediate feasibility and efficacy of TC-325 application, as well as the rates of rebleeding at Day 8 and Day 30. Multivariate analysis was performed to determine predictive factors of rebleeding. <b>Results:</b> A total of 202 patients were enrolled and 64 endoscopists participated from 20 centers. TC-325 was used as salvage therapy in 108 patients (53.5 %). The etiology of bleeding was an ulcer in 75 patients (37.1 %), tumor in 61 (30.2 %), postendoscopic therapy in 35 (17.3 %), or other in 31 (15.3 %). Application of the hemostatic powder was found to be very easy or easy in 31.7 % and 55.4 %, respectively. The immediate efficacy rate was 96.5 %. Recurrence of UGIB was noted at Day 8 and Day 30 in 26.7 % and 33.5 %, respectively. Predictive factors of recurrence at Day 8 were melena at initial presentation and use of TC-325 as salvage therapy. <b>Conclusion:</b> These multicenter data confirmed the high rate of immediate hemostasis, excellent feasibility, and good safety profile of TC-325, which could become the treatment of choice in bleeding tumors or postendoscopic bleeding but not in bleeding ulcers where randomized studies are needed. Trial registration: ClinicalTrials.gov (NCT02595853)
Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810
Authors: Gerald S. Falchook, Rom Leidner, Elizabeth Stankevich, Brian Piening, Carlo Bifulco, Israel Lowy, Matthew G. Fury
Journal: Journal for ImmunoTherapy of Cancer (2016)

Basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (CSCC) share exposure to UV light as the dominant risk factor, and these tumors therefore harbor high mutation burdens. In other malignancies, high mutation burden has been associated with clinical benefit from therapy with antibodies directed against the Programmed Death 1 (PD-1) immune checkpoint receptor. Highly mutated tumors are more likely to express immunogenic tumor neoantigens that attract effector T cells, which can be unleashed by blockade of the PD-1 immune checkpoint.This report describes a patient with metastatic BCC and a patient with metastatic CSCC who were treated with REGN2810, a fully human anti-PD-1 monoclonal antibody, in an ongoing phase 1 trial (NCT02383212). The CSCC patient has experienced an ongoing complete response (16+ months), and the BCC patient has experienced an ongoing partial response (12+ months).These case reports suggest that UV-associated skin cancers, beyond melanoma, are sensitive to PD-1 blockade.Clinicaltrials.gov NCT02383212. Registered 2 February 2015.
Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication
Authors: Adriaan J. van der Meer, Jordan J. Feld, Harald Hofer, Piero L. Almasio, Vincenza Calvaruso, Conrado M. Fernández-Rodríguez, Soo Aleman, Nathalie Ganne-Carrié, Roberta D’Ambrosio, Stanislas Pol, Maria Trapero-Marugan, Raoel Maan, Ricardo Moreno-Otero, Vincent Mallet, Rolf Hultcrantz, Ola Weiland, Karoline Rutter, Vito Di Marco, Sonia Alonso, Savino Bruno, Massimo Colombo, Robert J. de Knegt, Bart J. Veldt, Bettina E. Hansen, Harry L.A. Janssen
Journal: Journal of Hepatology (2016)
Autologous Transplantation for Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL).
Authors: Uday Popat, Chitra Hosing, Michelle Fanale, L. Jeffrey Medeiros, Amin M. Alousi, Sergio A. Giralt, Marcos J. de Lima, Muzaffar H. Qazilbash, Partow Kebriaei, Anas Younes, Issa Khouri, Borje Andersson, Richard Champlin, Paolo Anderlini
Journal: Blood (2009)
The role of reduced glutathione on oxaliplatin-induced neuropathy in colorectal cancer patients
Authors: G. Lelli, G. Romano, R. Ardito, A. Bochicchio, A. Capobianco, M. Coccaro, P. Di Leo, A. Tartarone, C. Romano, N. Calvi, V. Lorusso
Journal: Journal of Clinical Oncology (2007)

19539 Background: Peripheral sensory neuropathy is a common side-effect of oxaliplatin based chemotherapy. The neuropathy is cumulative and dose-related. Symptoms include sensory ataxia and dysesthesia of the limbs, mouth, throat and larynx, and may be exacerbated by exposure to cold. Studies suggest that Glutathione (GSH) is neuroprotective against oxaliplatin-induced neuropathy. Methods: From Jan. 2004, 83 consecutive colorectal cancer patients (pts) elegibile to oxaliplatin-based regimen were treated with GSH 1500 mg/mq over a 15-minute infusion period before oxaliplatin. Treatment-related toxicity was evaluated based on National Cancer Institute (NCI) Criteria. Results: After four cycles of chemotherapy, 5 pts (6%) experienced G1 neurotoxicity. After eight cycles, 2 pts (2.4%) experienced G2 sensory neuropathy (duration &lt; 7 days) and 8 (9.6%) pts G1. After 12 cycles, G3 sensory neuropathy was observed in 2 pts (2.4%), G2 in 8 (9.6%) and G1 in 11 pts (13%). Neither G4 sensory neuropathy was registered nor treatment interruption was required. Conclusions: These findings suggest that use of GSH may protect from oxaliplatin-induced neuropathy. In fact, in our series, only 2 (2.4%) pts experienced severe paresthesia interfering with daily activities and none hade permanent sensory loss. However, only a well designed randomised controlled study will definitely prove the protective effect of GSH on oxaliplatin induced neurotoxicity. No significant financial relationships to disclose.
Side Population of Multiple Myeloma and Multiple Myeloma Stem Cell
Authors: Kyoung Ha Kim, Hee-Jeong Cheong, Sook-Ja Kim, Se Hyung Kim, Jina Yoon, Han Jo Kim, Hyun Jung Kim, Sang-Cheol Lee, Sang Byung Bae, Chan-Kyu Kim, Namsu Lee, Kyu Taeg Lee, Sung Kyu Park, Dae Sik Hong, Jong-Ho Won, Hyun Jung Jun, Myung Hee Chang
Journal: Blood (2014)
Abstract IA18: Latency and immune evasion of metastatic stem cells
Authors: Joan Massagué
Journal: Cancer Research (2016)

Abstract Metastasis frequently develops years after the removal of a primary tumor, from a minority of disseminated cancer cells that survived as latent entities. An improved understanding of the location and survival mechanisms of disseminated cancer cells, and their ability to enter a quiescent state, evade immune surveillance, and retain tumor reinitiating capacity is needed to better prevent and treat metastatic cancer. To this end, we isolated latency competent cancer (LCC) cells from early-stage human lung and breast carcinoma cell lines and defined the mechanisms that prevent the outgrowth, support the long-term survival, and maintain the tumor-initiating potential of these cells during latent metastasis. LCC cells show stem cell-like characteristics and express Sox transcription factors, which are essential for their survival in host organs under restrictive conditions and for metastatic outgrowth under permissive conditions. Through autocrine suppression of WNT signaling and heightened TGF-β signaling, LCC cells self-impose a slow-cycling state with broad down-regulation of NK cell activators. By actively entering quiescence, these metastatic stem cells can evade innate immunity to remain latent for extended periods. Citation Format: Joan Massagué. Latency and immune evasion of metastatic stem cells. [abstract]. In: Proceedings of the AACR Special Conference: Function of Tumor Microenvironment in Cancer Progression; 2016 Jan 7–10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2016;76(15 Suppl):Abstract nr IA18.
Efficiency Of 7+3 Chemotherapy Followed By Donor Lymphocyte Infusion In Patients With Relapsed Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation
Authors: Rashit Bogdanov, Larisa Mendeleeva, Elena Parovichnikova, Larisa Kuzmina, Irina Galtseva, Valeri G. Savchenko
Journal: Blood (2013)
Development of an index to define overall disease severity in IBD
Authors: Corey A Siegel, Cynthia B Whitman, Brennan M R Spiegel, Brian Feagan, Bruce Sands, Edward V Loftus, Remo Panaccione, Geert D'Haens, Charles N Bernstein, Richard Gearry, Siew C Ng, Gerassimos J Mantzaris, Balfour Sartor, Mark S Silverberg, Robert Riddell, Ioannis E Koutroubakis, Colm O'Morain, Peter L Lakatos, Dermot P B McGovern, Jonas Halfvarson, Walter Reinisch, Gerhard Rogler, Wolfgang Kruis, Curt Tysk, Stefan Schreiber, Silvio Danese, William Sandborn, Anne Griffiths, Bjorn Moum, Christoph Gasche, Francesco Pallone, Simon Travis, Julian Panes, Jean-Frederic Colombel, Stephen Hanauer, Laurent Peyrin-Biroulet
Journal: Gut (2016)

Background and aim Disease activity for Crohn's disease (CD) and UC is typically defined based on symptoms at a moment in time, and ignores the long-term burden of disease. The aims of this study were to select the attributes determining overall disease severity, to rank the importance of and to score these individual attributes for both CD and UC. Methods Using a modified Delphi panel, 14 members of the International Organization for the Study of Inflammatory Bowel Diseases (IOIBD) selected the most important attributes related to IBD. Eighteen IOIBD members then completed a statistical exercise (conjoint analysis) to create a relative ranking of these attributes. Adjusted utilities were developed by creating proportions for each level within an attribute. Results For CD, 15.8% of overall disease severity was attributed to the presence of mucosal lesions, 10.9% to history of a fistula, 9.7% to history of abscess and 7.4% to history of intestinal resection. For UC, 18.1% of overall disease severity was attributed to mucosal lesions, followed by 14.0% for impact on daily activities, 11.2% C reactive protein and 10.1% for prior experience with biologics. Overall disease severity indices were created on a 100-point scale by applying each attribute's average importance to the adjusted utilities. Conclusions Based on specialist opinion, overall CD severity was associated more with intestinal damage, in contrast to overall UC disease severity, which was more dependent on symptoms and impact on daily life. Once validated, disease severity indices may provide a useful tool for consistent assessment of overall disease severity in patients with IBD.
The Anti-Myeloma Effect of Bortezomib Is Associated with Osteoblastic Activity.
Authors: Maurizio Zangari, Kevin B. Najarian, Dixie L. Esseltine, Choon-Kee Lee, Bart Barlogie, Francesca Elice, Michael J. Burns, Shmuel Yaccoby, Paul Richardson, Pieter Sonneveld
Journal: Blood (2005)
CPX-351 ((Cytarabine:Daunorubicin) Liposome Injection, (Vyxeos)) Does Not Prolong Qtcf Intervals, Requires No Dose Adjustment for Impaired Renal Function and Induces High Rates of Complete Remission in Acute Myeloid Leukemia
Authors: Tara L. Lin, Laura F. Newell, Robert K. Stuart, Laura C. Michaelis, Stephen E. Rubenstein, Helen S. Pentikis, Timothy Callahan, Donna Alvarez, Lawrence D. Mayer, Arthur C. Louie
Journal: Blood (2015)
Erythropoietin modulation is associated with improved homing and engraftment after umbilical cord blood transplantation
Authors: Omar S. Aljitawi, Soumen Paul, Avishek Ganguly, Tara L. Lin, Sid Ganguly, George Vielhauer, Maegan L. Capitano, Amy Cantilena, Brea Lipe, Jonathan D. Mahnken, Amanda Wise, Abigale Berry, Anurag K. Singh, Leyla Shune, Christopher Lominska, Sunil Abhyankar, Dennis Allin, Mary Laughlin, Joseph P. McGuirk, Hal E. Broxmeyer
Journal: Blood (2016)
Health-Related Quality of Life After Concussion
Authors: Douglas R. Polster, Christopher C. Giza, Talin Babikian
Journal: JAMA Pediatrics (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Bcl-x Prevents the Apoptosis of Late-Stage, Hemoglobin-Synthesizing Erythroblasts, but It Does Not Mediate the Anti-Apoptotic Effect of Erythropoietin on Early-Stage Erythroblasts.
Authors: Melissa M. Rhodes, Prapaporn Kopsombut, Maurice Bondurant, James O. Price, Mark J. Koury
Journal: Blood (2004)